Franz-Werner Haas
Chief Executive Officer at Curevac Aktiebolag
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philippe Dro | M | 61 |
LimmaTech Biologics AG
 LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | 9 years |
| Michael Kowarik | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | 9 years |
| Michael Wacker | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | 9 years |
| Paul Wolfarm | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | 9 years |
| Veronica Fonck | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | - |
| Zina Affas Besse | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | 1 years |
| Patricia Martin | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | - |
| Giovanni Della Cioppa | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | - |
| Malte Greune | M | 59 | 3 years | |
| Antony Blanc | M | 57 | 4 years | |
| Viola Bronsema | M | 61 | 4 years | |
| Carsten Nils Erik Browall | M | 66 |
Curevac Aktiebolag
 Curevac Aktiebolag Containers/PackagingProcess Industries Part of Curevac International AB, Curevac Aktiebolag is a Swedish company that manufactures vacuum bags for smaller food producers. The private company is based in Gothenburg, Sweden. Franz-Werner Haas has been the CEO of the company since 2012. | - |
| Craig Tooman | M | 58 | 5 years | |
| Camilla Hansen | M | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | 1 years |
| Debra Stephanie Barker | M | 61 | 2 years | |
| Mathias Hothum | M | 58 | 9 years | |
| Kabeer Aziz | M | 34 |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | 1 years |
| Alexander Zehnder | M | 54 | 1 years | |
| Pierre Kemula | M | 50 | 8 years | |
| Baron Jean Stéphenne | M | 73 | 9 years | |
| Klaus Schollmeier | M | 67 | 2 years | |
| Myriam Mendila | M | 58 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ingmar Hoerr | M | - | 20 years | |
| Michael Wolf | M | - | 8 years | |
| Timothy Sullivan | M | 66 | 11 years | |
| Frank Rathgeb | M | - | 4 years | |
| Florian von der Muelbe | M | 52 | 21 years | |
| Friedrich von Bohlen und Halbach | M | 60 | - | |
| Hans Tanner | M | 72 | 8 years | |
| Alfred Bach | M | - | - | |
| Wolf-Dieter Starp | M | - | 2 years | |
| Kevin Holme | M | - |
Lion Bioscience, Inc.
 Lion Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Lion Bioscience, Inc. provides integrated solutions for genomics and bioinformatics. The private company is based in Cambridge, MA. | 2 years |
| Ralf Clemens | M | 71 | 8 years | |
| Mariola Fotin-Mleczek | M | 50 | 16 years | |
| Timothy M. Wright | M | 69 | 3 years | |
| Klaus Edvardsen | M | 62 | 1 years | |
| Bernd Winterhalter | M | 65 | 2 years | |
| Igor Splawski | M | 56 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 25 | 65.79% |
| Switzerland | 10 | 26.32% |
| United States | 2 | 5.26% |
| Sweden | 1 | 2.63% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Franz-Werner Haas
- Personal Network